Provided by Tiger Fintech (Singapore) Pte. Ltd.

iBio

0.7258
-0.0042-0.58%
Volume:328.02K
Turnover:237.10K
Market Cap:11.77M
PE:-0.31
High:0.7299
Open:0.7268
Low:0.7159
Close:0.7300
Loading ...

iBio Is Maintained at Buy by Chardan Capital

Dow Jones
·
25 Jun

iBio, AstralBio unveil obesity program with amylin receptor agonist antibody

TIPRANKS
·
24 Jun

BRIEF-Ibio And Astralbio Unveil Obesity Program With Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results

Reuters
·
24 Jun

Ibio and Astralbio Unveil Obesity Program With Novel Amylin Agonist Antibody Demonstrating Promising in Vivo Results

THOMSON REUTERS
·
24 Jun

Ibio Inc - Amylin Receptor Agonist Antibody Reduces Food Intake in Mouse Model

THOMSON REUTERS
·
24 Jun

Ibio Inc - Antibody-Based Agonists Show Potential for Obesity and Cardiometabolic Diseases

THOMSON REUTERS
·
24 Jun

iBio Inc. Announces Extension of Promissory Note with Safi Biotherapeutics, Requires Interest Payment for Extension

Reuters
·
18 Jun

Trump Says Pharma Tariffs Coming Very Soon

Reuters
·
17 Jun

BRIEF-IBio Initiates Non-Human Primate Study Of First-In-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention In Weight Regain After GLP-1 Treatment

Reuters
·
16 Jun

iBio initiates non-human primate study of IBIO-610

TIPRANKS
·
16 Jun

Ibio Inc - Preclinical Results Show 26% Fat Reduction With Ibio-610

THOMSON REUTERS
·
16 Jun

Ibio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After Glp-1 Treatment

THOMSON REUTERS
·
16 Jun

Ibio Inc - Ibio-610 Prevents Weight Regain in Mice After Glp-1 Therapy

THOMSON REUTERS
·
16 Jun

Ibio Inc - Ibio-610 Drives 8.9% Body Weight Loss in Mice

THOMSON REUTERS
·
16 Jun

IBio Files Prospectus for Resale of About 11.3 Million Shares

MT Newswires Live
·
13 Jun

Vaccine Stocks Surge with Moderna up 11%

Tiger Newspress
·
20 May

Trump Says He Will Cut Drug Prices by 59%

Reuters
·
12 May

iBio Is Maintained at Buy by Chardan Capital

Dow Jones
·
05 May

Ibio’s First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy With Glp-1S in Preclinical Model

THOMSON REUTERS
·
05 May

iBio’s First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model

GlobeNewswire
·
05 May